Werewolf Therapeutics, Inc. announced that an abstract providing an update of the Company’s ongoing monotherapy and combination Phase 1/1b study of WTX-124, its interleukin 2 INDUKINE™ molecule, has been accepted for poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting, taking place May 31 - June 4 in Chicago, Illinois.
April 24, 2024
· 4 min read